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Objective: Previous studies have suggested the amelioration of lung reperfusion
injury when initial reperfusion is undertaken with leukocyte-depleted blood. Phar-
macologic agents, such as pentoxifylline, are also effective, but no previous studies
have demonstrated which is superior. We investigated these agents in a porcine
model of left single-lung transplantation.
Methods: Donor lungs were preserved with modified Euro-Collins solution for a
mean ischemic time of 18.6 hours. Gas exchange, pulmonary vascular resistance,
neutrophil elastase level, and free radical release (measured on the basis of malon-
aldehyde levels) were assessed over a 12-hour period. Group A (n  5) was a
control group with no interventions added. Group B was reperfused through an
extracorporeal circuit incorporating a leukocyte-depleting filter for 30 minutes
before conventional blood flow was restored. Group C was reperfused with the
addition of intravenous pentoxifylline (2 mg · kg1 · h1).
Results: Groups B and C were similar in terms of oxygenation, pulmonary vascular
resistance, and free radical release. Group B displayed increased levels of neutrophil
elastase. Both groups were superior with regard to these outcome measures com-
pared with control group A.
Conclusions: Pentoxifylline, when administered to recipient animals, attenuates
reperfusion injury to a degree similar to that seen with leukocyte-depleted reperfu-
sion. This technique is simple, safe, and as effective as using a more complex
extracorporeal circuit incorporating a leukocyte-depleting filter to ameliorate acute
lung injury.
Despite advances in lung preservation technology, early graft dys-function remains a significant problem. The pathophysiology oflung graft ischemia-reperfusion injury is complex but predomi-nantly involves the sequestration of leukocytes in the lung, withsubsequent release of toxic granular enzymes and oxygen freeradicals.1
Several interventions are thought to modulate reperfusion injury but have seldom
been directly compared in a single standardized model. Some of the more promising
interventions include the administration of intravenous pentoxifylline and, alterna-
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tively, the perfusion of the graft lung with leukocyte-de-
pleted blood obtained by using a suitable filter contained
within an extracorporeal circuit.
Pentoxifylline administration has been successful in
ameliorating reperfusion injury after skeletal muscle isch-
emia and experimental lung and liver transplantation. It acts
through a variety of mechanisms, including inhibition of
leukocyte-endothelial interactions and oxygen free radical
scavenging. There might also be inhibitory effects on cyto-
kines.
Leukocyte-depleting filters have been used in heart-lung
transplant models when incorporated into the cardiopulmo-
nary bypass circuit and in isolated rat lung grafts.2,3 Signif-
icantly improved early graft function has been achieved
compared with that seen in control animals. Recent experi-
ence with the reperfusion of human lung grafts indicates
that this is a potentially useful intervention to ameliorate
early graft dysfunction.4
We investigated the comparative benefits of these inter-
ventions and were uniquely able to directly compare their
effects in a porcine model of single-lung transplantation
with follow-up for 12 hours. This enabled us to assess which
intervention might be superior for subsequent use in clinical
practice.
Methods
Fifteen female Landrace pigs (mean weight, 45.6 kg) were divided
randomly into 3 groups (n  5 in each). A similar number were
size and weight matched and acted as donor animals. All grafts
were reperfused at a mean pulmonary artery pressure of 20 mm
Hg.
Group A was a control group with no intervention adminis-
tered. Group B was perfused through a leukocyte-depleting filter
for the first 30 minutes of reperfusion and then perfused ordinarily
through the pulmonary artery. Group C was reperfused with the
addition of intravenous pentoxifylline (20 mg/kg loading dose,
followed by 2 mg · kg1 · h1). Pentoxifylline was administered
to the recipient animal only and commenced 5 minutes before
reperfusion of the graft.
All animals received humane care in compliance with the
“Principles of Laboratory Animal Care” formulated by the Na-
tional Society for Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the National Acad-
emy of Science and published by the National Institutes of Health
(National Institutes of Health publication no. 85-23, revised 1985).
All conditions associated with the United Kingdom Animals (Sci-
entific Procedures) Act of 1986 were also met.
Donor Operation
Our model of single-lung transplantation has been described pre-
viously.5 In summary, animals were anesthetized with initial in-
tramuscular premedication by using diazemuls (2 mg/kg) and
ketamine (15 mg/kg). Subsequent anesthesia was induced with
propofol (20 mg/kg) and maintained with isoflurane and intrave-
nous alfentanil. Animals were intubated with an endotracheal tube
(outside diameter, 9.5 mm) and ventilated at a tidal volume of 15
mL/kg at an inspired oxygen concentration of 100%.
Heart-lung blocks were retrieved in a standard manner, and
lungs were preserved by means of flush perfusion with 60 mL/kg
modified Euro-Collins solution administered through the main
pulmonary artery.
After separation of the left lung from the block, a pulmonary
artery pressure monitoring line (Cavafix Certo 18G; Braun, Mel-
sungen, Germany) was inserted through a purse-string suture into
the distal left pulmonary artery. A pulmonary venous sampling line
(Flocare; Nutricia, Madrid, Spain) was similarly placed through
the left atrial cuff directed into a distal pulmonary vein, allowing
for later sampling of venous blood from the graft to avoid the
mixing of blood from the contralateral native lung. Lungs were
stored inflated at a temperature of 4°C for a mean ischemic time of
18.6 hours.
Recipient Operation
Recipient animals were premedicated with intramuscular azaper-
one (8 mg/kg) and diazemuls (2 mg/kg). After induction with
intravenous propofol, animals were maintained on intravenous
pentobarbitone (30 mg · kg1 · h1) and alfentanil. Venous and
arterial pressure monitoring lines were inserted as in donor ani-
mals.
Two endotracheal tubes were inserted through a tracheostomy.
A 9.5-mm outside diameter tube was placed into the trachea to
ventilate both lungs initially and, subsequently the native lung
alone. The second 6.5-mm tube was advanced through the left
bronchial anastomosis after its completion to ventilate the graft
lung independently. Each endotracheal tube was connected to a
separate ventilator to permit individual lung ventilation after trans-
plantation, with a tidal volume of 15 mL/kg at 12 breaths/min for
each lung. The fraction of inspired oxygen was 100%.
A left thoracotomy was performed, followed by a left pneumo-
nectomy. Implantation of the donor lung proceeded in an estab-
lished fashion, constructing anastomoses of the left atrium, bron-
chus, and left pulmonary artery in order. The contralateral
pulmonary artery was encircled by a tape and snugger such that the
left pulmonary artery pressure could be manipulated. A pressure
monitoring line was placed in the recipient left atrium, and a
dedicated sampling line was inserted into the proximal left pul-
monary artery.
Pulmonary artery flow was measured by using a 10-mm Tran-
sonic A-Series flow probe (Linton Instruments, Norfolk, United
Kingdom) placed around the left pulmonary artery distal to the
anastomotic line. A similar 12-mm probe was placed around the
descending aorta to provide a guide to the cardiac output. Both
flow probes were connected to a dual-channel HT207 Medical
volume flowmeter (Transonic Systems Inc, Ithaca, NY).
All data sources were routed through a CED 1401 32-channel
digital to analogue converter (Cambridge Electronic Design Ltd,
Cambs, United Kingdom) and acquired on a microcomputer by
using Spike 2 (Version 4.0) data acquisition software (Cambridge
Electronic Design Ltd). Data were collected continually over the
12-hour postoperative period and stored on hard disk for subse-
quent analysis.
Animals in group A received no intervention to modulate
reperfusion injury and acted as a control group apart from systemic
Clark et al Cardiothoracic Transplantation
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 6 2053
TX
heparinization (300 U/kg). Because the pulmonary artery pressure
at reperfusion might influence subsequent graft function, the pres-
sure was kept at 20 mm Hg by constricting or releasing the
tourniquet on the contralateral pulmonary artery as required. The
same principle was applied to the other groups to ensure that
reperfusion pressure was constant in all cases.
In animals randomized to group B, a simple circuit was used to
allow preliminary leukocyte-depleted perfusion of the graft lung.
Blood was drawn from the external jugular vein through a large-
bore cannula (Polystan Venous Paediatric Catheter 145016 16FG;
Polystan A/S, Walgerholm, Denmark) and passed through 3-in
tubing through a calibrated roller pump, distal to which a Pall
BC1-B leukocyte-depleting cardioplegia filter (Pall Biomedical,
Portsmouth, United Kingdom) was placed. This filter combines
leukocyte filtration technology with a conventional gaseous and
particulate microemboli-removing 40-m screen. The filter has
been designed to allow flow rates of up to 500 mL/min while
retaining the ability to efficiently filter leukocytes.
Beyond this, a cannula (Polystan Bent Hard Tip 18FG 100184,
Polystan A/S) returned filtered blood to the left pulmonary artery.
The cannula was inserted into the artery through a purse-string
suture proximal to the anastomotic suture line and then advanced
past the anastomosis such that the tip lay just proximal to the left
upper lobe artery branch. With the left pulmonary artery occluded
proximally, the lung could be reperfused by blood from the filter
circuit for 30 minutes at a pressure of 20 mm Hg, after which the
vessel was decannulated, allowing flow from the recipient pulmo-
nary artery to enter the pulmonary vascular bed. Three hundred
units per kilogram of heparin was administered as a bolus to the
animal before cannulation of the pulmonary artery. The experi-
ment was then executed as usual. Blood remaining in the circuit
(priming volume, 500 mL) was returned slowly to the animal over
a 2-hour period through the remaining external jugular venous
cannula.
Group C animals received intravenous pentoxifylline, which
was commenced 5 minutes before reperfusion of the lung graft. A
loading dose bolus of 20 mg/kg was administered, followed by an
infusion of 2 mg · kg1 · h1 for the duration of the experiment.
Animals in group C also received 300 U/kg heparin to match the
pharmacologic conditions of Group B. No untoward effects of
drug administration were noted in any animal.
In all animals the pulmonary venous oxygen partial pressure (in
millimeters of mercury) was obtained from pulmonary venous
sampling line samples analyzed immediately on a blood gas ana-
lyzer (Nova Biomedical Stat Profile 5, Waltham, Mass).
Pulmonary vascular resistance (PVR; in millimeters of mercury
per liter per minute) was calculated on the basis of the following
formula:
(Mean pulmonary artery pressure [mm Hg])
 (Left atrial pressure [mm Hg])
Left pulmonary flow [L/min].
Malonaldehyde (MDA), an important decomposition product
of lipid peroxides, is an indirect measure of free radical activity. A
spectrophotometric assay using an LPO-586 method (Calbiochem-
Novabiochem International, San Diego, Calif) was used to quan-
tify MDA in pulmonary venous blood.
Five-milliliter samples of whole blood were collected in 48 L
of potassium ethylenediamine tetraacetic acid, 0.17 mol/L. After
centrifugation at 2500g for 10 minutes at 4°C, 200 L of the
supernatant was collected in duplicate for use in the assay. The
sample was incubated for 40 minutes at 45°C with the chromo-
genic substance and then cooled on ice, and absorbance was
measured with a spectrophotometer at 586 nm. The sensitivity of
this method was determined as 0.5 mol/L. In whole blood sam-
ples of 200 L, the lower limit of measurable MDA was 2.5
mol/L. Reproducibility was determined by using assays per-
formed over 10 days under identical experimental conditions. By
using standard concentrations from 0 to 20 mol/L, the SEM was
less than 5%.
For the assay of neutrophil elastase, blood (5 mL) was collected
in ethylenediamine tetraacetic acid and centrifuged within 2 hours
of collection at 3000 rpm (1500g) for 10 minutes. Fifty-microliter
specimens of plasma or control samples were added to 2500 L of
phosphate-buffered saline. All samples were duplicated at this
stage. One thousand microliters of distilled water was added before
incubation for 60 minutes at 25°C. Five hundred microliters of
antibody-enzyme solution was then added, and after a further
incubation of 30 minutes (25°C), the sample was washed 3 times
with distilled water, and 500 L of substrate solution was added
(20 mol of 4-nitrophenyl phosphate/10 mL of diethaolamine [pH
9.8] 1 mol/L, magnesium chloride 0.5 mmol/L). The reaction was
terminated with 100 L of sodium hydroxide (2 mol/L) after a
further 30 minutes of incubation protected from light.
Five hundred microliters of the sample with 100 L of sodium
hydroxide was then used to measure absorbance at 405 nm. The
mean absorbance from the duplicate determinations was calcu-
lated. The concentration of elastase from the absorbance of each
sample was then determined from the calibration curve. Results
were thus received in micrograms per liter of neutrophil elastase.
Free hemoglobin did not affect the assay, which was of importance
in leukocyte filter experiments in which free hemoglobin levels at
the upper limit of the normal range were observed.
Statistical Methods
A misleading impression might be gained of trends in data because
graphically a line joining mean values together might not describe
individual subjects within a study group adequately. Furthermore,
no account is taken of the fact that measurements at different time
points are from the same subjects with successive observations of
an individual subject likely to be correlated.6 Statistical examina-
tion using the individual, rather than the mean of the group at each
time point, as the basic unit for analysis can be performed to
overcome these potential problems. A single number to summarize
an individual subject’s response curve with time must be sought
(ie, a summary measure). This reduces a large number of depen-
dent observations to a smaller number of summary measures.
In our study the summary measure of area under the curve was
used to describe the behavior of individual animals. Groups of
animals were then compared by using Scheffe analysis of variance.
Results
The perfusion of lungs at 20 mm Hg with leukocyte-
depleted blood for 30 minutes before normal pressure reper-
fusion conferred significant benefits in terms of gas ex-
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change. The pulmonary venous oxygen partial pressure, as
assessed by the summary measure of area under the curve,
was significantly higher than that in control animals sub-
jected to similar pressure control at the time of reperfusion
(P  .001).
In comparison with lungs reperfused with the addition of
the pharmacologic intervention, a similar pulmonary venous
oxygen partial pressure was observed in pentoxifylline-
treated animals. No significant difference in oxygenation
was seen when comparing leukocyte filtration and pentoxi-
fylline treatment (P  .414). No difference in partial pres-
sure of carbon dioxide was noted in either treatment group
compared with that in the control animals (P  .05, Figure
1).
MDA levels (a measure of oxygen free radical activity)
were significantly less in groups B and C than in group A (P
 .05). Groups B and C were similar, however (P  .05,
Figure 2).
Analysis of neutrophil elastase indicated that higher lev-
els were observed in lungs reperfused through the filter.
Elastase levels after filtration were significantly higher than
in control lungs (P  .002) or lungs treated with pentoxi-
fylline (P  .001). Elastase levels were, however, signifi-
cantly less in animals treated with pentoxifylline compared
with those in control animals (P  .001). The high levels of
elastase in group B were probably a result of the degree of
neutrophil activation during circulation through the extra-
corporeal circuit and hemolysis (Figure 3).
PVR for filtered lungs was significantly less than that
seen in control animals (P  .0001), but PVR was similar
when compared with that in lungs reperfused with the
addition of pentoxifylline (P  .95, Figure 4).
Left atrial pressures and right ventricular pressures were
no different in filter group animals compared with pressures
in any other group (P  .05).
Repeated sampling did not significantly affect the hemat-
ocrit level of animals in any group over the time course of
the experiment.
Figure 1. Pulmonary venous oxygen partial pressure (PVO2; in
millimeters of mercury) with time after reperfusion. Results are
shown as the mean value for 5 animals in each intervention
group. Error bars indicate the 95% confidence interval. Figure 2. MDA levels with time after reperfusion. Results are
shown as the mean value for 5 animals in each intervention
group. Error bars indicate the 95% confidence interval. Prereper-
fusion value is shown at time zero.
Figure 3. Elastase levels with time after reperfusion. Results are
shown as the mean value for 5 animals in each intervention
group. Error bars indicate the 95% confidence interval. Prereper-
fusion value is shown at time zero.
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Discussion
In our experiments groups B and C were similar in terms of
oxygenation, PVR, and free radical release. Group B, how-
ever, displayed increased levels of neutrophil elastase,
which is likely to be a reflection of hemolysis and neutrophil
activation in an extracorporeal circuit.
Both groups were superior with regard to these outcome
measures compared with control group A. Pentoxifylline,
when administered to recipient animals, attenuates reperfu-
sion injury to a degree similar to that seen with leukocyte-
depleted reperfusion. We believe that the simple infusion of
a pharmacologic agent is simple, safe, and as effective as
using a more complex extracorporeal circuit incorporating a
leukocyte-depleting filter to ameliorate acute lung injury.
Our model of left single-lung transplantation provided a
stable and reproducible apparatus, permitting control of
ventilation and perfusion of the lung graft while the animal
was supported by the contralateral lung, irrespective of the
function in the newly implanted graft. The rigorous separa-
tion of the lungs in terms of sample collection ensures that
there is no mixing of blood from the contralateral side.
Importantly, this study enables direct comparisons to be
made between various interventions thought to be of benefit
in attenuating reperfusion injury. The removal of leukocytes
from blood reperfusing the transplanted lung is surely the
gold standard against which other interventions must be
measured. The disadvantages of neutrophil activation by an
extracorporeal circuit, however, are a well-recognized prob-
lem with such systems.
Pentoxifylline appears to be a promising agent in com-
bating reperfusion injury in a variety of organs and has
certainly been shown to be beneficial in lung injury.7-10
Until now, no comparison has ever been made with leuko-
cyte depletion under consistent conditions in the same
model.
The concept of leukocyte depletion is not new. In 1928,
Fleming used cotton wool filters to extract white cells from
whole blood, and the filtration of whole blood to deplete it
of leukocytes has been practiced since 1962. Modern spe-
cific leukocyte filters are formed from tightly packed fibers
of combed cotton, nylon, or cellulose acetate. The mode of
action is not completely understood because the filters not
only retain activated and adherent neutrophils but also lym-
phocytes, monocytes, and some platelets.
Using advanced 40-m polyester screen technology,
manufacturers have developed biocompatible extracorpo-
real leukocyte-depletion filters capable of effective neutro-
phil removal that could be incorporated into the arterial
return line of a cardiopulmonary bypass circuit. Gourlay and
colleagues11,12 have indicated the efficacy of leukocyte de-
pletion of the filter in both pulsatile and nonpulsatile bypass.
The role of white cell depletion in transplantation was
previously investigated by using a bovine model.2 After 12
hours of hypothermic preservation, heart-lung transplanta-
tions were performed with study animals undergoing reper-
fusion through a Pall RC100 filter in the return arm of the
cardiopulmonary bypass system. During a 4-hour follow-up
period, filtered animals had improved survival, better arte-
rial oxygen tension, less extravascular lung water, and re-
duced systemic leukocyte counts. Combining superoxide
dismutase administration with the use of leukocyte-depleted
reperfusion further improved lung function after transplan-
tation.
The ability of leukocyte-free reperfusion to prolong lung
preservation times and retain satisfactory graft function was
further confirmed by Schueler and associates.13 After core
cooling during cardiopulmonary bypass, bovine lungs were
preserved for 24 hours. After double-lung transplantation,
reperfusion with a leukocyte-depleting filter in the extracor-
poreal circuit reduced the leukocyte count to 3% of its
original value and improved systemic oxygenation, airway
pressures, and lung water content and lowered PVR com-
pared with that seen in control animals.
Our evaluation of the BC1B filter indicated that, from a
purely practical standpoint, lungs could be reperfused from
this extracorporeal circuit for 30 minutes before the 12-hour
evaluation began, showing that a relatively easy method for
extracorporeal perfusion of a unilateral lung graft can be
effectively and safely accomplished.
In our experiments 30 minutes of leukocyte-depleted
reperfusion protects the lung from subsequent injury. This
could result from the downregulation of neutrophil-endo-
Figure 4. PVR with time after reperfusion. Results are shown as
the mean value for 5 animals in each intervention group. Error
bars indicate the 95% confidence interval. Prereperfusion value is
shown at time zero.
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thelial adhesion molecules, which must occur during the
initial phase of reperfusion and ameliorates neutrophil trap-
ping in the lung graft. Recent studies on an isolated rabbit
lung have also indicated that short periods of leukocyte-
depleted reperfusion are beneficial, although the mechanism
has yet to be investigated.14 A recent investigation in human
lung transplant recipients used arterial blood collected and
mixed to make a 4:1 solution of blood and modified Buck-
berg perfusate. This solution was passed through a leuko-
cyte filter and into the transplanted pulmonary artery for 10
minutes at a controlled rate and pressure (20 mm Hg)
immediately before removal of the vascular clamp. All 5
patients in this clinical series demonstrated excellent post-
reperfusion function in the lung grafts.4
Interestingly, neutrophil elastase levels were increased in
those lungs reperfused by the filter and probably reflect a
degree of hemolysis and neutrophil activation as blood
passes through the filter and extracorporeal circuit. Pulmo-
nary venous oxygenation was similar to that achieved with
pentoxifylline but superior to that seen in the control group.
PVR was comparable with that seen in the pharmacologic
intervention group and was again superior to unmodified
reperfusion in the control group.
Pentoxifylline has many functions, in particular inhibit-
ing the adherence of neutrophils to endothelium and pre-
venting leukocyte degranulation. It might also inhibit inter-
leukin 1 and tumor necrosis factor, which are critical in the
pathogenesis of ischemia-reperfusion injury. Pentoxifylline
clearly improves and augments pulmonary function by re-
ducing neutrophil trapping in the lung and subsequent free
radical release.15-17
Previous studies in large-animal models in Europe and in
North America have demonstrated improvements in func-
tional outcome when the agent is incorporated into either
the lung preservation flush solution or administered imme-
diately before reperfusion.8,9,18 Our own studies comparing
pentoxifylline with controlled pressure reperfusion and
other pharmacologic interventions (eg, nitric oxide donors
and phytic acid derivatives) have confirmed the effective-
ness of this agent. Clearly pentoxifylline, when adminis-
tered to the recipient only, confers significant advantages by
attenuating reperfusion injury and permitting longer isch-
emic times to be tolerated. Little is known of function
beyond 12 hours or the optimal dosing regimen, and this
needs to be addressed in future studies.
Pentoxifylline, already licensed for use in human sub-
jects with peripheral vascular disease, is an inexpensive and
safe drug for use in lung transplant recipients and appears to
be at least as effective as leukocyte-depleted blood reper-
fusion. It obviates the need for complex and expensive
extracorporeal circuits and filters and the dangers with
which they are inevitably associated in the operating room
setting.
Adoption of pentoxifylline, a simple and cheap interven-
tion, in human lung graft recipients might lead to consider-
able improvements in mortality and morbidity among lung
transplant recipients, as well as shorter intensive care stays
and costs.
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